Benefits on some inflammatory mediators, but they are specific for some supplementation protocols (duration, dose, route) and concomitant anti-cancer treatment: reduction in IL-6 occurs in surgical patients that received 0.2 g/kg of FO parenterally at postoperative period (p = 0.002); increase in albumin occurs in surgical patients that received >2.5 g/d of EPA+DHA orally at preoperative period (p = 0.038); in patients undergoing chemo- therapy, the supplementation of 0.6 g/d of EPA+DHA during 9 week reduces CRP levels (p = 0.017), and CRP/albumin ratio (p = 0.016). Here, ALB is linked to cancer.